Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, United States of America.
Biomed Phys Eng Express. 2022 Feb 1;8(2). doi: 10.1088/2057-1976/ac3f4e.
Radiation epidemiology studies of childhood cancer survivors treated in the pre-computed tomography (CT) era reconstruct the patients' treatment fields on computational phantoms. For such studies, the phantoms are commonly scaled to age at the time of radiotherapy treatment because age is the generally available anthropometric parameter. Several reference size phantoms are used in such studies, but reference size phantoms are only available at discrete ages (e.g.: newborn, 1, 5, 10, 15, and Adult). When such phantoms are used for RT dose reconstructions, the nearest discrete-aged phantom is selected to represent a survivor of a specific age. In this work, we (1) conducted a feasibility study to scale reference size phantoms at discrete ages to various other ages, and (2) evaluated the dosimetric impact of using exact age-scaled phantoms as opposed to nearest age-matched phantoms at discrete ages.We have adopted the University of Florida/National Cancer Institute (UF/NCI) computational phantom library for our studies. For the feasibility study, eight male and female reference size UF/NCI phantoms (5, 10, 15, and 35 years) were downscaled to fourteen different ages which included next nearest available lower discrete ages (1, 5, 10 and 15 years) and the median ages at the time of RT for Wilms' tumor (3.9 years), craniospinal (8.0 years), and all survivors (9.1 years old) in the Childhood Cancer Survivor Study (CCSS) expansion cohort treated with RT. The downscaling was performed using our in-house age scaling functions (ASFs). To geometrically validate the scaling, Dice similarity coefficient (DSC), mean distance to agreement (MDA), and Euclidean distance (ED) were calculated between the scaled and ground-truth discrete-aged phantom (unscaled UF/NCI) for whole-body, brain, heart, liver, pancreas, and kidneys. Additionally, heights of the scaled phantoms were compared with ground-truth phantoms' height, and the Centers for Disease Control and Prevention (CDC) reported 50th percentile height. Scaled organ masses were compared with ground-truth organ masses. For the dosimetric assessment, one reference size phantom and seventeen body-size dependent 5-year-old phantoms (9 male and 8 female) of varying body mass indices (BMI) were downscaled to 3.9-year-old dimensions for two different radiation dose studies. For the first study, we simulated a 6 MV photon right-sided flank field RT plan on a reference size 5-year-old and 3.9-year-old (both of healthy BMI), keeping the field size the same in both cases. Percent of volume receiving dose ≥15 Gy (V) and the mean dose were calculated for the pancreas, liver, and stomach. For the second study, the same treatment plan, but with patient anatomy-dependent field sizes, was simulated on seventeen body-size dependent 5- and 3.9-year-old phantoms with varying BMIs. V, mean dose, and minimum dose received by 1% of the volume (D), and by 95% of the volume (D) were calculated for pancreas, liver, stomach, left kidney (contralateral), right kidney, right and left colons, gallbladder, thoracic vertebrae, and lumbar vertebrae. A non-parametric Wilcoxon rank-sum test was performed to determine if the dose to organs of exact age-scaled and nearest age-matched phantoms were significantly different (p < 0.05).In the feasibility study, the best DSCs were obtained for the brain (median: 0.86) and whole-body (median: 0.91) while kidneys (median: 0.58) and pancreas (median: 0.32) showed poorer agreement. In the case of MDA and ED, whole-body, brain, and kidneys showed tighter distribution and lower median values as compared to other organs. For height comparison, the overall agreement was within 2.8% (3.9 cm) and 3.0% (3.2 cm) of ground-truth UF/NCI and CDC reported 50th percentile heights, respectively. For mass comparison, the maximum percent and absolute differences between the scaled and ground-truth organ masses were within 31.3% (29.8 g) and 211.8 g (16.4%), respectively (across all ages). In the first dosimetric study, absolute difference up to 6% and 1.3 Gy was found for Vand mean dose, respectively. In the second dosimetric study, Vand mean dose were significantly different (p < 0.05) for all studied organs except the fully in-beam organs. Dand Dwere not significantly different for most organs (p > 0.05).We have successfully evaluated our ASFs by scaling UF/NCI computational phantoms from one age to another age, which demonstrates the feasibility of scaling any CT-based anatomy. We have found that dose to organs of exact age-scaled and nearest aged-matched phantoms are significantly different (p < 0.05) which indicates that using the exact age-scaled phantoms for retrospective dosimetric studies is a better approach.
在计算机断层扫描(CT)时代之前接受治疗的儿童癌症幸存者的放射流行病学研究,通过计算体模重建患者的治疗区域。对于此类研究,通常根据放射治疗时的年龄对体模进行缩放,因为年龄是一般可用的人体测量参数。此类研究中使用了几个参考大小的体模,但参考大小的体模仅在离散的年龄可用(例如:新生儿、1 岁、5 岁、10 岁、15 岁和成人)。当此类体模用于 RT 剂量重建时,选择最接近的离散年龄体模来代表特定年龄的幸存者。在这项工作中,我们 (1) 进行了一项可行性研究,将离散年龄的参考大小体模缩放到各种其他年龄,以及 (2) 评估了使用精确年龄缩放体模与在离散年龄时使用最接近年龄匹配的体模相比的剂量学影响。我们为我们的研究采用了佛罗里达大学/国家癌症研究所 (UF/NCI) 的计算体模库。对于可行性研究,将八个男性和女性参考大小的 UF/NCI 体模(5、10、15 和 35 岁)缩放到十四个不同的年龄,包括下一个可用的较低离散年龄(1、5、10 和 15 岁)和接受 RT 的威尔姆斯瘤(3.9 岁)、颅脊髓(8.0 岁)和儿童癌症幸存者研究(CCSS)扩展队列中所有幸存者(9.1 岁)的中位数年龄。缩放是使用我们内部的年龄缩放函数 (ASF) 进行的。为了对缩放进行几何验证,计算了缩放和地面真实离散年龄体模(未缩放的 UF/NCI)之间的 Dice 相似系数 (DSC)、平均距离一致性 (MDA) 和欧几里得距离 (ED),用于全身、大脑、心脏、肝脏、胰腺和肾脏。此外,还比较了缩放体模的高度与地面真实体模的高度,以及疾病控制和预防中心 (CDC) 报告的 50 百分位高度。比较了缩放器官的质量与地面真实器官的质量。对于剂量评估,将一个参考大小的体模和十七个身体大小依赖的 5 岁体模(9 名男性和 8 名女性)缩放到 3.9 岁的尺寸,用于两种不同的辐射剂量研究。在第一项研究中,我们模拟了一个 6 MV 光子右侧侧腹场 RT 计划在参考大小 5 岁和 3.9 岁(均为健康 BMI),在两种情况下保持相同的场大小。计算了胰腺、肝脏和胃的接受剂量≥15 Gy(V)和平均剂量。在第二项研究中,使用患者解剖相关的场大小模拟了相同的治疗计划,但对于十七个身体大小依赖的 5 岁和 3.9 岁体模,具有不同的 BMI。计算了胰腺、肝脏、胃、左肾(对侧)、右肾、右结肠、胆囊、胸椎和腰椎的 V、平均剂量和 1%体积(D)接受的最小剂量,以及 95%体积(D)接受的最小剂量。使用非参数 Wilcoxon 秩和检验确定器官的剂量是否显著不同(p < 0.05)。在可行性研究中,大脑(中位数:0.86)和全身(中位数:0.91)获得了最佳 DSCs,而肾脏(中位数:0.58)和胰腺(中位数:0.32)的一致性较差。在 MDA 和 ED 方面,全身、大脑和肾脏的分布更紧密,中位数值较低。对于身高比较,整体一致性在地面真实 UF/NCI 和 CDC 报告的 50 百分位高度的 2.8%(3.9 厘米)和 3.0%(3.2 厘米)之间。对于质量比较,缩放器官质量与地面真实器官质量的最大百分比和绝对差异分别在 31.3%(29.8 克)和 211.8 克(16.4%)之间(所有年龄)。在第一项剂量研究中,V 和平均剂量的绝对值差异分别高达 6%和 1.3 Gy。在第二项剂量研究中,除了完全在束内的器官外,所有研究器官的 Vand 平均剂量均有显著差异(p < 0.05)。D 和 D 大多数器官的差异不显著(p > 0.05)。我们通过将 UF/NCI 计算体模从一个年龄缩放至另一个年龄成功评估了我们的 ASF,这证明了缩放任何基于 CT 的解剖结构的可行性。我们发现,精确年龄缩放和最接近年龄匹配体模的器官剂量显著不同(p < 0.05),这表明在回顾性剂量学研究中使用精确年龄缩放体模是一种更好的方法。